Cost-effectiveness analysis of budesonide/formoterol (Symbicort ®) as needed for mild asthma in Malaysia

ConclusionFrom the Malaysian healthcare payer perspective, budesonide/formoterol PRN is either a dominant or likely to be a cost-effective treatment option in managing mild asthma.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research